Breaking News

CND Life Sciences Receives $4.2M Grant from MJFF

Will support a clinical initiative to investigate the use of the Syn-One Test to quantify abnormal phosphorylated alpha-synuclein in patients with Parkinson's.

Author Image

By: Charlie Sternberg

Associate Editor

CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker services, has been awarded a $4.2 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).   The award will support an 18-month clinical initiative, the Syn-Q Study, to investigate the use of the Syn-One Test to quantify abnormal phosphorylated alpha-synuclein in patients with Parkinson’s disease over time. Syn-One is ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters